Lundbeck secures EU approval for Cipralex successor
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorization for Lundbeck's multi-modal depression therapy Brintellix (vortioxetine) for the treatment of adults with major depressive episodes (depression). The European approval follows approval by the US FDA in September (scripintelligence.com, 1 October 2013).